Ekstedt M - Search Results

1

Long-term follow-up of patients with NAFLD and elevated liver enzymes.

Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Ekstedt M, et al. Hepatology. 2006 Oct;44(4):865-73. doi: 10.1002/hep.21327. Hepatology. 2006. PMID: 17006923

2

[New reference interval for ALAT does not identify subclinical liver disease. Lower limit than the proposed should be used for medical considerations!].

Kechagias S, Ekstedt M, Mathiesen UL, Franzén L. Kechagias S, et al. Among authors: ekstedt m. Lakartidningen. 2004 Sep 16;101(38):2884-7. Lakartidningen. 2004. PMID: 15485172 Swedish.

3

Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting.

Franzén LE, Ekstedt M, Kechagias S, Bodin L. Franzén LE, et al. Among authors: ekstedt m. Mod Pathol. 2005 Jul;18(7):912-6. doi: 10.1038/modpathol.3800370. Mod Pathol. 2005. PMID: 15920560 Free article.

4

Development of an unbiased method for the estimation of liver steatosis.

Franzén L, Ekstedt M, Kechagias S, Bodin L. Franzén L, et al. Among authors: ekstedt m. Clin Transplant. 2005 Aug;19(4):571; author reply 572. doi: 10.1111/j.1399-0012.2005.00380.x. Clin Transplant. 2005. PMID: 16008608 No abstract available.

5

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.

Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Ekstedt M, et al. J Hepatol. 2007 Jul;47(1):135-41. doi: 10.1016/j.jhep.2007.02.013. Epub 2007 Mar 8. J Hepatol. 2007. PMID: 17400325

6

Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy.

Noren B, Dahlqvist O, Lundberg P, Almer S, Kechagias S, Ekstedt M, Franzén L, Wirell S, Smedby O. Noren B, et al. Among authors: ekstedt m. Eur J Radiol. 2008 May;66(2):313-20. doi: 10.1016/j.ejrad.2007.06.004. Epub 2007 Jul 23. Eur J Radiol. 2008. PMID: 17646074

7

Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability.

Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, Kechagias S, Poynard T, Olsson R. Ratziu V, et al. Among authors: ekstedt m. Aliment Pharmacol Ther. 2007 Sep 15;26(6):821-30. doi: 10.1111/j.1365-2036.2007.03425.x. Aliment Pharmacol Ther. 2007. PMID: 17767466 Free article.

8

Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.

Ekstedt M, Franzén LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, Kechagias S. Ekstedt M, et al. Scand J Gastroenterol. 2009;44(3):366-74. doi: 10.1080/00365520802555991. Scand J Gastroenterol. 2009. PMID: 19016382

9

Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation.

Boström EA, Ekstedt M, Kechagias S, Sjöwall C, Bokarewa MI, Almer S. Boström EA, et al. Among authors: ekstedt m. Scand J Immunol. 2011 Nov;74(5):463-70. doi: 10.1111/j.1365-3083.2011.02592.x. Scand J Immunol. 2011. PMID: 21671974 Free article.

10

Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.

Ekstedt M, Franzén LE, Mathiesen UL, Kechagias S. Ekstedt M, et al. Scand J Gastroenterol. 2012 Jan;47(1):108-15. doi: 10.3109/00365521.2011.634024. Epub 2011 Nov 30. Scand J Gastroenterol. 2012. PMID: 22126450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters